Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Oct;8(1-2):25-50.
doi: 10.1007/BF03033818.

Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases

Affiliations
Review

Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases

I Kadiu et al. Neurotox Res. 2005 Oct.

Abstract

Brain mononuclear phagocytes (MP, bone marrow monocyte-derived macrophages, perivascular macrophages, and microglia) function to protect the nervous system by acting as debris scavengers, killers of microbial pathogens, and regulators of immune responses. MP are activated by a variety of environmental cues and such inflammatory responses elicit cell injury and death in the nervous system. MP immunoregulatory responses include secretion of neurotoxic factors, mobilization of adaptive immunity, and cell chemotaxis. This incites tissue remodelling and blood-brain barrier dysfunction. As disease progresses, MP secretions engage neighboring cells in a vicious cycle of autocrine and paracrine amplification of inflammation leading to tissue injury and ultimately destruction. Such pathogenic processes tilt the balance between the relative production of neurotrophic and neurotoxic factors and to disease progression. The ultimate effects that brain MP play in disease revolves "principally" around their roles in neurodegeneration. Importantly, common functions of brain MP in neuroimmunity link highly divergent diseases (for example, human immunodeficiency virus type-one associated dementia, Alzheimer's disease and Parkinson's disease). Research into this process from our own laboratories and those of others seek to harness MP inflammatory processes with the intent of developing therapeutic interventions that block neurodegenerative processes and improve the quality of life in affected people.

PubMed Disclaimer

References

    1. J Immunol. 1989 Dec 1;143(11):3517-23 - PubMed
    1. J Exp Med. 1983 Nov 1;158(5):1522-36 - PubMed
    1. J Neurosci. 1996 Apr 15;16(8):2508-21 - PubMed
    1. Glia. 1997 Mar;19(3):190-8 - PubMed
    1. Restor Neurol Neurosci. 2000;16(2):135-142 - PubMed

Publication types

LinkOut - more resources